{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:13Z","timestamp":1792292593698,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600038C"],"award-info":[{"award-number":["HHSO100201600038C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.diagmicrobio.2025.116711","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T07:57:40Z","timestamp":1737964660000},"page":"116711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-9019","authenticated-orcid":false,"given":"Michael D.","family":"Huband","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley A.","family":"Fedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden on bacterial antimicrobial resistance in 2019: a systemic analysis","volume":"399","author":"Murray Christophere","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0002","unstructured":"World Health Organization Bacterial Priority Pathogens List, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. ISBN 978-92-4-009346-1."},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0003","volume":"2019","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0004","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0005","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0006","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0007","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and preclinical review of omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0008","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0009","series-title":"Omadacycline is not a substrate for clinically relevant beta-lactamase enzymes. ASM-ESCMID","author":"Mendes","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0010","series-title":"Recognized antimicrobial susceptiblity test interpretive criteria for omadacycline","year":"2024"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0011","doi-asserted-by":"crossref","first-page":"e02262","DOI":"10.1128\/AAC.02262-18","article-title":"Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in mainland China, Hong Kong, and Taiwan: results from the SENTRY antimicrobial surveillance program (2013 to 2016)","volume":"63","author":"Carvalhaes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY antimicrobial surveillance programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0013","doi-asserted-by":"crossref","first-page":"e00018","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Western Pacific) collection (2010-2011)","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0014","doi-asserted-by":"crossref","first-page":"e02411","DOI":"10.1128\/AAC.02411-16","article-title":"Activities of omadacycline and comparator agents when tested against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","article-title":"Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014)","volume":"90","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2018.01.019","article-title":"Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0017","doi-asserted-by":"crossref","first-page":"e02327","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116711_bib0018","doi-asserted-by":"crossref","first-page":"e02488","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016-2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2021.09.011","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States: report from the SENTRY antimicrobial surveillance program, 2019","author":"Pfaller","year":"2021","journal-title":"J Global Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0020","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0021","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0022","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute acterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomized, controlled, non-inferiority trial","volume":"10","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0023","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: twelveth edition","year":"2024"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0024","series-title":"Performance standards for antimcirobial susceptibility testing: 34th informational supplement","year":"2024"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2025.116711_bib0026","doi-asserted-by":"crossref","first-page":"ofae470","DOI":"10.1093\/ofid\/ofae470","article-title":"Hight rates of nonsusceptibility to common oral antibiotics in Streptococcus pneumoniae clinical isolates from the United States (2019-2021)","volume":"11","author":"Deshpande","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2025.116711_bib0027","first-page":"952","article-title":"Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections","volume":"29","author":"Lodise","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2025.116711_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2025.116711_bib0029","doi-asserted-by":"crossref","first-page":"ofad335","DOI":"10.1093\/ofid\/ofad335","article-title":"Long-term safety and tolerability of omadacycline for the treatment of mycobacterium abscessus infections","volume":"10","author":"Mingora","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116711_bib0030","article-title":"Empiric treatment approach for the management of post-operative incisional infections with omadacycline","volume":"3","author":"Wrotslavsky","year":"2023","journal-title":"Foot Ankle Surg Case Rep Ser"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116711_bib0031","first-page":"1715","article-title":"Real-world, multicenter case series of patients treated with oral omadacycline for resistant gram-negative pathogens","volume":"11","author":"Morrisette","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0032","unstructured":"Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results From an Open-Label, Non-inferiority, randomized controlled trial IDWeek 2024 October 16-20, 2024 Los Angeles, CA."},{"key":"10.1016\/j.diagmicrobio.2025.116711_bib0033","unstructured":"Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs) IDWeek 2022 October 19-23, 2022 Washington DC."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:20:38Z","timestamp":1778692838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0732889325000343"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116711","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116711"}}